MS
MCID: MLT020
MIFTS: 78

Multiple Sclerosis (MS)

Categories: Genetic diseases, Rare diseases, Neuronal diseases

Aliases & Classifications for Multiple Sclerosis

MalaCards integrated aliases for Multiple Sclerosis:

Name: Multiple Sclerosis 57 38 12 76 53 25 54 75 37 55 6 43 44 15 73
Ms 57 53 25 75
Multiple Sclerosis, Disease Progression, Modifier of 57 13
Multiple Sclerosis Modifier of Disease Progression 29 6
Disseminated Sclerosis 57 25
Multiple Sclerosis, Susceptibility to, 1 57
Multiple Sclerosis, Susceptibility to 57
Multiple Sclerosis Susceptibility to 40
Generalized Multiple Sclerosis 12
Multiple Sclerosis 1 57
Insular Sclerosis 12

Characteristics:

OMIM:

57
Inheritance:
multifactorial

Miscellaneous:
onset 20-55 years of age
women affected more than men (3:2)
association with the hla-drb1*1501-dqb1*0602 haplotype has been repeatedly demonstrated in high-risk (northern european) populations.


HPO:

32
multiple sclerosis:
Inheritance multifactorial inheritance


Classifications:



Summaries for Multiple Sclerosis

NINDS : 54 An unpredictable disease of the central nervous system, multiple sclerosis (MS) can range from relatively benign to somewhat disabling to devastating, as communication between the brain and other parts of the body is disrupted.  Many investigators believe MS to be an autoimmune disease -- one in which the body, through its immune system, launches a defensive attack against its own tissues. In the case of MS, it is the nerve-insulating myelin that comes under assault. Such assaults may be linked to an unknown environmental trigger, perhaps a virus. Most people experience their first symptoms of MS between the ages of 20 and 40; the initial symptom of MS is often blurred or double vision, red-green color distortion, or even blindness in one eye.  Most MS patients experience muscle weakness in their extremities and difficulty with coordination and balance.  These symptoms may be severe enough to impair walking or even standing. In the worst cases, MS can produce partial or complete paralysis.  Most people with MS also exhibit paresthesias, transitory abnormal sensory feelings such as numbness, prickling, or "pins and needles" sensations.  Some may also experience pain.  Speech impediments, tremors, and dizziness are other frequent complaints. Occasionally, people with MS have hearing loss. Approximately half of all people with MS experience cognitive impairments such as difficulties with concentration, attention, memory, and poor judgment, but such symptoms are usually mild and are frequently overlooked.  Depression is another common feature of MS.

MalaCards based summary : Multiple Sclerosis, also known as ms, is related to pediatric multiple sclerosis and acute disseminated encephalomyelitis, and has symptoms including back pain, headache and hemiplegia. An important gene associated with Multiple Sclerosis is PDCD1 (Programmed Cell Death 1), and among its related pathways/superpathways are Cell adhesion molecules (CAMs) and MicroRNAs in cancer. The drugs 4-Aminopyridine and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include Neural Tube and Limb, and related phenotypes are diplopia and emotional lability

UniProtKB/Swiss-Prot : 75 Multiple sclerosis: A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheath, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease.

NIH Rare Diseases : 53 Multiple sclerosis (MS) is a degenerative disorder that affects the central nervous system, specifically the brain and the spinal cord. The disorder is characterized by destruction of the myelin, the fatty tissue that surrounds and protects the nerve fibers and promotes the transmission of nerve impulses, and damage to nerve cells. The symptoms vary widely from person to person, and may include sensory disturbances in the limbs, problems with muscle control, tremors, muscle stiffness (spasticity), exaggerated reflexes (hyperreflexia), weakness, difficulty walking, poor bladder control, and vision problems. Most patients have periods during which they have symptoms (clinical attacks). The clinical attacks are typically followed by periods without any symptoms (remission). After several years, the symptoms worsen continuously. Multiple sclerosis is considered an autoimmune disorder but the exact cause is unknown. Risk factors for developing multiple sclerosis include genetic factors like changes in the HLA-DRB1 gene and in the IL7R gene and environmental factors, such as exposure to the Epstein-Barr virus, low levels of vitamin D, and smoking. The goal of treatment of MS is to decrease attacks and the inflammation within the central nervous system.

MedlinePlus : 43 Multiple sclerosis (MS) is a nervous system disease that affects your brain and spinal cord. It damages the myelin sheath, the material that surrounds and protects your nerve cells. This damage slows down or blocks messages between your brain and your body, leading to the symptoms of MS. They can include Visual disturbances Muscle weakness Trouble with coordination and balance Sensations such as numbness, prickling, or "pins and needles" Thinking and memory problems No one knows what causes MS. It may be an autoimmune disease, which happens when your immune system attacks healthy cells in your body by mistake. Multiple sclerosis affects women more than men. It often begins between the ages of 20 and 40. Usually, the disease is mild, but some people lose the ability to write, speak, or walk. There is no single test for MS. Doctors use a medical history, physical exam, neurological exam, MRI, and other tests to diagnose it. There is no cure for MS, but medicines may slow it down and help control symptoms. Physical and occupational therapy may also help. NIH: National Institute of Neurological Disorders and Stroke

Genetics Home Reference : 25 Multiple sclerosis is a condition characterized by areas of damage (lesions) on the brain and spinal cord. These lesions are associated with destruction of the covering that protects nerves and promotes the efficient transmission of nerve impulses (the myelin sheath) and damage to nerve cells. Multiple sclerosis is considered an autoimmune disorder; autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs, in this case tissues of the nervous system.

Disease Ontology : 12 A demyelinating disease that involves damage to the fatty myelin sheaths around the axons of the brain and spinal cord resulting in demyelination and scarring.

Wikipedia : 76 Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the... more...

Description from OMIM: 126200

Related Diseases for Multiple Sclerosis

Diseases in the Multiple Sclerosis family:

Multiple Sclerosis 2 Multiple Sclerosis 3
Multiple Sclerosis 4 Multiple Sclerosis 5
Secondary Progressive Multiple Sclerosis Primary Progressive Multiple Sclerosis

Diseases related to Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 593)
# Related Disease Score Top Affiliating Genes
1 pediatric multiple sclerosis 34.9 HLA-DQB1 HLA-DRB1
2 acute disseminated encephalomyelitis 33.9 HLA-DQB1 HLA-DRB1 MBP
3 hypersomnia 33.7 HLA-DQB1 HLA-DRB1
4 autoimmune disease 32.1 HLA-DQB1 HLA-DRB1 MBP PDCD1
5 autoimmune hepatitis 31.5 HLA-DQB1 HLA-DRB1 PDCD1
6 guillain-barre syndrome 31.3 HLA-DQB1 MBP TNFRSF1A
7 pityriasis rosea 31.0 HLA-DQB1 HLA-DRB1
8 lichen sclerosus 30.9 HLA-DQB1 HLA-DRB1
9 endometriosis 30.0 MIR145 MIR20A MIR223
10 primary biliary cirrhosis 29.7 MIR20A MIR223 MIR326
11 marburg acute multiple sclerosis 12.4
12 relapsing-remitting multiple sclerosis 12.4
13 secondary progressive multiple sclerosis 12.4
14 primary progressive multiple sclerosis 12.3
15 multiple sclerosis 3 12.3
16 tumefactive multiple sclerosis 12.3
17 progressive relapsing multiple sclerosis 12.3
18 multiple sclerosis 5 12.3
19 disseminated sclerosis with narcolepsy 12.0
20 multiple sclerosis 2 12.0
21 multiple sclerosis 4 12.0
22 multiple sclerosis-ichthyosis-factor viii deficiency syndrome 11.9
23 neuromyelitis optica 11.7
24 leukodystrophy, demyelinating, adult-onset, autosomal dominant 11.5
25 limbic encephalitis with lgi1 antibodies 11.4 HLA-DQB1 HLA-DRB1
26 trigeminal neuralgia 11.4
27 optic neuritis 11.4
28 metal allergy 11.4 HLA-DQB1 HLA-DRB1
29 focal epithelial hyperplasia 11.3 HLA-DQB1 HLA-DRB1
30 lichen planopilaris 11.3 HLA-DQB1 HLA-DRB1
31 type ii mixed cryoglobulinemia 11.3 HLA-DQB1 HLA-DRB1
32 beryllium disease 11.3 HLA-DQB1 HLA-DRB1
33 recurrent respiratory papillomatosis 11.3 HLA-DQB1 HLA-DRB1
34 autoimmune pancreatitis 11.3 HLA-DQB1 HLA-DRB1
35 pars planitis 11.2
36 spasticity 11.2
37 chronic beryllium disease 11.2 HLA-DQB1 HLA-DRB1
38 progressive multifocal leukoencephalopathy 11.2
39 cerebral atrophy 11.2
40 tremor 11.1
41 intermediate uveitis 11.1
42 whipple disease 11.1 HLA-DQB1 HLA-DRB1
43 optic nerve disease 11.1
44 foot drop 11.1
45 dysphagia 11.1
46 leber hereditary optic neuropathy 11.1
47 nervous system disease 11.1
48 retinal vasculitis 11.1
49 pseudobulbar affect 11.1
50 stiff-person syndrome 11.1

Comorbidity relations with Multiple Sclerosis via Phenotypic Disease Network (PDN):


Acute Cystitis Decubitus Ulcer
Neurogenic Bladder Paraplegia
Trigeminal Neuralgia

Graphical network of the top 20 diseases related to Multiple Sclerosis:



Diseases related to Multiple Sclerosis

Symptoms & Phenotypes for Multiple Sclerosis

Symptoms via clinical synopsis from OMIM:

57
Head And Neck Eyes:
diplopia
vision loss, monocular

Neurologic Peripheral Nervous System:
incoordination
weakness
paresthesias
sensory loss

Laboratory Abnormalities:
increased csf immunoglobulin levels
oligoclonal bands in csf
myelin basic protein in csf

Neurologic Central Nervous System:
emotional lability
spasticity
depression
high intensity area in white matter on head mri
cognitive dysfunction
more
Genitourinary Bladder:
incomplete bladder emptying
incontinence
hesitancy


Clinical features from OMIM:

126200

Human phenotypes related to Multiple Sclerosis:

32 (show all 10)
# Description HPO Frequency HPO Source Accession
1 diplopia 32 HP:0000651
2 emotional lability 32 HP:0000712
3 depressivity 32 HP:0000716
4 spasticity 32 HP:0001257
5 muscle weakness 32 HP:0001324
6 paresthesia 32 HP:0003401
7 urinary incontinence 32 HP:0000020
8 incoordination 32 HP:0002311
9 urinary hesitancy 32 HP:0000019
10 cns demyelination 32 HP:0007305

UMLS symptoms related to Multiple Sclerosis:


back pain, headache, hemiplegia, muscle cramp, pain, sciatica, seizures, syncope, tremor, chronic pain, vertigo/dizziness, sleeplessness

Drugs & Therapeutics for Multiple Sclerosis

Drugs for Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 634)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
4-Aminopyridine Approved Phase 4,Phase 3,Phase 2,Phase 1 504-24-5 1727
2
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
3
Natalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 189261-10-7
4
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
5
Interferon beta-1b Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 145155-23-3
6
Glatiramer Acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147245-92-9 3081884
7
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
8
Ethanol Approved Phase 4,Phase 3,Not Applicable 64-17-5 702
9
Gabapentin Approved, Investigational Phase 4,Phase 2,Not Applicable 60142-96-3 3446
10
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 2,Not Applicable 56-12-2 119
11
Interferon beta-1a Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 145258-61-3 6438354
12
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 65271-80-9 4212
13
Simvastatin Approved Phase 4,Phase 3,Phase 2 79902-63-9 54454
14
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-61-6, 62-31-7 681
15
Memantine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 19982-08-2 4054
16 Titanium dioxide Approved Phase 4,Phase 2 13463-67-7
17
Methotrexate Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 1959-05-2, 59-05-2 126941
18
Iron Approved Phase 4,Early Phase 1 7439-89-6 23925
19
Menthol Approved Phase 4,Phase 1,Not Applicable,Early Phase 1 2216-51-5 16666
20
alemtuzumab Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 216503-57-0
21
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
22
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1 174722-31-7 10201696
23
Armodafinil Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 112111-43-0
24
Modafinil Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 68693-11-8 4236
25
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 69-65-8 453 6251
26
Lamotrigine Approved, Investigational Phase 4,Phase 2 84057-84-1 3878
27
Topiramate Approved Phase 4,Phase 2 97240-79-4 5284627
28
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
29
Acetylcholine Approved Phase 4,Phase 3,Phase 2 51-84-3 187
30 Piracetam Approved, Investigational Phase 4 7491-74-9
31
Aspirin Approved, Vet_approved Phase 4,Phase 3,Early Phase 1 50-78-2 2244
32
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 624-49-7 5271565 637568
33
Donepezil Approved Phase 4,Phase 3 120014-06-4 3152
34
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-27-2 5288826
35
Dronabinol Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 1972-08-3 16078
36
Peppermint oil Approved, Investigational Phase 4,Phase 3 8006-90-4
37
Montelukast Approved Phase 4,Phase 1,Phase 2 158966-92-8 5281040
38
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
39
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
40
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
41
Oxybutynin Approved, Investigational Phase 4 5633-20-5 4634
42
Calcium Carbonate Approved, Investigational Phase 4 471-34-1
43
Cetirizine Approved Phase 4,Phase 1 83881-51-0 2678
44
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75614-87-8, 51-45-6 774
45
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 103-90-2 1983
46
Acyclovir Approved Phase 4,Phase 3,Phase 1 59277-89-3 2022
47
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
48
Ibuprofen Approved Phase 4,Phase 3 15687-27-1 3672
49
Ranitidine Approved Phase 4,Phase 3 66357-59-3, 66357-35-5 3001055
50
Cephalexin Approved, Investigational, Vet_approved Phase 4 15686-71-2 27447

Interventional clinical trials:

(show top 50) (show all 1865)
# Name Status NCT ID Phase Drugs
1 Impact of Vitamin A on Multiple Sclerosis (MS) Unknown status NCT01417273 Phase 4 Drug: placebo
2 Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient Unknown status NCT01407211 Phase 4
3 Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine. Unknown status NCT02849782 Phase 4 Fampridine
4 Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS Unknown status NCT02259361 Phase 4 Sustained-release oral dalfampridine;Placebo
5 Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis Unknown status NCT01705457 Phase 4 Dietary Supplement: vitamin A;placebo
6 Methylprednisolone During the Switch Between Natalizumab and Fingolimod Unknown status NCT02769689 Phase 4 Methylprednisolone;Placebo;natalizumab (NTZ);fingolimob (FTY)
7 Resistance Training and Amino Pyridine in Multiple Sclerosis Unknown status NCT02143167 Phase 4 SR-fampridine;Placebo
8 Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS) Unknown status NCT01339676 Phase 4 Colecalciferol;Placebo capsules
9 Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) Unknown status NCT00910598 Phase 4 glatiramer acetate
10 Efficacy of MBI for Depressive Symptoms in Patients With MS Unknown status NCT02611401 Phase 4
11 Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya Unknown status NCT02325440 Phase 4 Fingolimod;Natalizumab
12 Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI Unknown status NCT00176592 Phase 4 Betaseron;Copaxone
13 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
14 Bladder Lavage as Decontamination Method for Asymptomatic Bacteriuria With Uropathogens in Catheterized Patients Unknown status NCT01772875 Phase 4
15 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Unknown status NCT01838174 Phase 4 ACTHAR Gel (ACTH);IV steroids with oral taper
16 Vitamin D and Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4 Vitamin D drops;Placebo drops
17 Treatment for Alcohol Dependence With Gabapentin Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
18 Lubiprostone in Patients With Multiple Sclerosis Associated Constipation Completed NCT01236534 Phase 4 Lubiprostone;Placebo
19 A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device Completed NCT01791244 Phase 4 Rebif®
20 Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients Completed NCT01225289 Phase 4 Placebo
21 A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone Completed NCT01142466 Phase 4 Interferon beta-1a (Rebif)
22 A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis Completed NCT01216072 Phase 4 Fingolimod;Standard MS DMTs
23 Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients Completed NCT01968902 Phase 4
24 A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis Completed NCT02064816 Phase 4 Rebif®;Rebif®
25 Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis Completed NCT01795872 Phase 4
26 Levetiracetam in Central Pain in Multiple Sclerosis(MS) Completed NCT00423527 Phase 4 levetiracetam
27 Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients Completed NCT01201343 Phase 4 Interferon beta-1a
28 The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis Completed NCT00536120 Phase 4
29 Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis Completed NCT02090413 Phase 4 dimethyl fumarate;acetylsalicylic acid;ASA-Placebo
30 Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse Completed NCT01986998 Phase 4 Methylprednisolone 1250 mg/24h x3 days;Oral Methylprednisolone 625 mg/24h x3 days
31 A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties Completed NCT00315367 Phase 4 Donepezil HCI (drug)
32 Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse Completed NCT00753792 Phase 4 methylprednisolone;methylprednisolone;Placebo
33 Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients Completed NCT01895335 Phase 4 Teriflunomide
34 Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis Completed NCT01480076 Phase 4 Fampridine
35 Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis Completed NCT00078338 Phase 4 Rebif®;Copaxone®
36 Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis Completed NCT00492765 Phase 4 Interferon-beta-1a;Simvastatin;Placebo
37 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
38 A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients Completed NCT01964547 Phase 4 Sativex;Placebo
39 Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change Completed NCT01317004 Phase 4 Fingolimod;Standard MS DMT
40 Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis Completed NCT01310166 Phase 4 Fingolimod
41 Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany Completed NCT02125604 Phase 4 dimethyl fumarate
42 Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™ Completed NCT02254304 Phase 4 Rebif
43 Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera Completed NCT02410278 Phase 4 dimethyl fumarate;montelukast;Placebo
44 A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis Completed NCT01356940 Phase 4 dalfampridine ER;placebo
45 Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications Completed NCT01834586 Phase 4 Anesthetic Topical Adhesive Synera
46 Memantine for Spasticity in MS Patients Completed NCT00638027 Phase 4 placebo;memantine
47 Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis Completed NCT00381264 Phase 4 Cesamet™ (nabilone)
48 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns Completed NCT01930799 Phase 4
49 Long-term Follow-up of Fingolimod Phase II Study Patients Completed NCT02307838 Phase 4
50 Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States Completed NCT01873417 Phase 4 BG00012 (DMF)

Search NIH Clinical Center for Multiple Sclerosis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Multiple Sclerosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Multiple Sclerosis:
Autologous bone marrow-derived hematopoietic stem cells for the treatment of multiple sclerosis
Bone marrow-derived mesenchymal stem cell transplantation for multiple sclerosis
Bone marrow-derived mesenchymal stem cell transplantation for treatment of multiple sclerosis
Bone marrow-derived stromal cells for multiple sclerosis
Epiblast stem cell-derived oligodendrocyte progenitor cells for multiple sclerosis
FCRx, bioengineered hematopoietic stem cells for immunological tolerance
Hematopoietic stem cells for multiple sclerosis
MultiStem
NU211-01/NU215-02, umbilical cord mesenchymal stem cells for multiple sclerosis and neuromyelitis optica
NurOwn
Peripheral blood-derived hematopoietic stem cells for treatment of multiple sclerosis
Placental-derived mesenchymal stem cells for treatment of multiple sclerosis
Stem cell-derived oligodendrocyte precursor cells for multiple sclerosis
Tcelna
Umbilical cord tissue-derived mesenchymal stem cells for teatment of multiple sclerosis
Embryonic/Adult Cultured Cells Related to Multiple Sclerosis:
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 19378207
Bone marrow-derived mesenchymal stem cells PMIDs: 22277374
Bone marrow-derived mesenchymal stem cells PMIDs: 21366911 22236384 22277374
Bone marrow-derived mesenchymal stem cells (family)
Oligodendrocyte progenitor cells PMIDs: 21946668
Facilitating cells PMIDs: 17150368
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 23205020 20637752 23020860 21175285 21248119
Umbilical cord-derived mesenchymal stem cells PMIDs: 20682053
Astrocyte-like cells PMIDs: 19127447 19603590
Peripheral blood-derived hematopoietic stem cells (family)
Placenta-derived mesenchymal stem cells PMIDs: 22638856
Oligodendrocyte precursor cells PMIDs: 19363151
Myelin-reactive T-cells PMIDs: 18465664 21563876 19230777
Umbilical cord-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: multiple sclerosis

Genetic Tests for Multiple Sclerosis

Genetic tests related to Multiple Sclerosis:

# Genetic test Affiliating Genes
1 Multiple Sclerosis Modifier of Disease Progression 29

Anatomical Context for Multiple Sclerosis

MalaCards organs/tissues related to Multiple Sclerosis:

41
Brain, T Cells, Spinal Cord, Testes, Bone, Monocytes, B Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Multiple Sclerosis:
# Tissue Anatomical CompartmentCell Relevance
1 Neural Tube Cortical Sub Ventricular Zone Adult Oligodendrocyte Precursor Cells Potential therapeutic candidate
2 Limb Pelvic Girdle Bone Marrow Stromal Cells Potential therapeutic candidate
3 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
4 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate
5 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
6 Spinal Cord Spinal Cord White Matter Myelinating Oligodendrocyte Cells Affected by disease
7 Brain Forebrain White Matter Myelinating Oligodendrocyte Cells Affected by disease
8 Brain Forebrain White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate
9 Neural Tube Caudal Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
10 Neural Tube dP5 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
11 Neural Tube Lateral Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
12 Neural Tube dP3 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
13 Neural Tube Motor Neural Progenitor Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
14 Neural Tube Anterior Entopeduncular Area Oligodendrocyte Precursor Cells Potential therapeutic candidate
15 Neural Tube Medial Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
16 Neural Tube dP4 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
17 Spinal Cord Spinal Cord White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate

Publications for Multiple Sclerosis

Articles related to Multiple Sclerosis:

(show top 50) (show all 6443)
# Title Authors Year
1
Pulmonary paracoccidioidomycosis associated with the use of natalizumab in multiple sclerosis. ( 29649930 )
2018
2
The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk. ( 29393768 )
2018
3
Cardiovascular Autonomic Dysfunction: Link Between Multiple Sclerosis Osteoporosis and Neurodegeneration. ( 29429076 )
2018
4
Cortical Excitability and Interhemispheric Connectivity in Early Relapsing-Remitting Multiple Sclerosis Studied With TMS-EEG. ( 29937712 )
2018
5
A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease. ( 29786964 )
2018
6
Association of Limb-Girdle muscular dystrophy with multiple sclerosis: A case report. ( 29387327 )
2018
7
Healthcare resources utilisation in primary progressive multiple sclerosis. ( 29637449 )
2018
8
Biopsy-proven multiple sclerosis in an adult patient with atypical craniometaphyseal dysplasia. ( 29444796 )
2018
9
Search for new biomarkers of pediatric multiple sclerosis: application of immunoglobulin free light chain analysis. ( 29408796 )
2018
10
Circulating exosomes suppress the induction of regulatory T cells via let-7i in multiple sclerosis. ( 29295981 )
2018
11
Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis. ( 29908077 )
2018
12
Utility of Two-Dimensional Difference Gel Electrophoresis in Diagnosis of Multiple Sclerosis. ( 29976874 )
2018
13
Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy. ( 29343163 )
2018
14
Correlation between cortical lesions and cognitive impairment in multiple sclerosis. ( 29974667 )
2018
15
The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. ( 29442178 )
2018
16
Addressing the targeting range of the ABILHAND-56 in relapsing-remitting multiple sclerosis: A mixed methods psychometric study. ( 29796290 )
2018
17
Five years before multiple sclerosis onset: Phenotyping the prodrome. ( 29979093 )
2018
18
The putative role of oxidative stress and inflammation in the pathophysiology of sleep dysfunction across neuropsychiatric disorders: Focus on chronic fatigue syndrome, bipolar disorder and multiple sclerosis. ( 29759891 )
2018
19
Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations. ( 29451440 )
2018
20
Cerebrospinal Fluid Cytokine Expression Profile in Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyneuropathy. ( 29182448 )
2018
21
Can Optical Coherence Tomography Be Used to Guide Treatment Decisions in Adult or Pediatric Multiple Sclerosis? ( 29564662 )
2018
22
Human miR-26a-5p regulates the glutamate transporter SLC1A1 (EAAT3) expression. Relevance in multiple sclerosis. ( 28962897 )
2018
23
Spinal Cord MRI in Multiple Sclerosis. ( 29157403 )
2018
24
Gut microbiome and pediatric multiple sclerosis. ( 29307301 )
2018
25
Expanding the Potential Therapeutic Options for Remote Ischemic Preconditioning: Use in Multiple Sclerosis. ( 29971043 )
2018
26
Animal models of multiple sclerosis: Focus on experimental autoimmune encephalomyelitis. ( 29446144 )
2018
27
Multiple sclerosis or "inflammatory CADASIL?": Case Report and review of the literature. ( 29449082 )
2018
28
Brain volume loss is present in Japanese multiple sclerosis patients with no evidence of disease activity. ( 29974307 )
2018
29
Global transcriptome profiling of mild relapsing-remitting versus primary progressive multiple sclerosis. ( 29316044 )
2018
30
Primary CNS Lymphoma vs. Tumefactive Multiple Sclerosis: A Diagnostic Challenge. ( 29290197 )
2018
31
Facial Myokymia and Hemifacial Spasm in Multiple Sclerosis: A Descriptive Study on Clinical Features and Treatment Outcomes. ( 29266036 )
2018
32
Efficacy of Percutaneous Posterior Tibial Nerve Stimulation for the Management of Fecal Incontinence in Multiple Sclerosis: A Pilot Study. ( 29575432 )
2018
33
Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus. ( 29380254 )
2018
34
Focal cortical thinning in patients with stable relapsing-remitting multiple sclerosis: cross-sectional-based novel estimation of gray matter kinetics. ( 29285552 )
2018
35
Usability of Telerehabilitation System Supporting Multipronged Exercise in Patients with Multiple Sclerosis. ( 29968658 )
2018
36
Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-I^-Treated Relapsing-Remitting-Multiple Sclerosis Patients. ( 29915590 )
2018
37
Evaluation of respiratory functions and quality of life in multiple sclerosis patients. ( 29974389 )
2018
38
Monosodium Urate Crystals Activate the Inflammasome in Primary Progressive Multiple Sclerosis. ( 29780394 )
2018
39
Correction to: Nebulization of RNS60, a Physically-Modified Saline, Attenuates the Adoptive Transfer of Experimental Allergic Encephalomyelitis in Mice: Implications for Multiple Sclerosis Therapy. ( 29611013 )
2018
40
Pediatric multiple sclerosis: current perspectives on health behaviors. ( 29595826 )
2018
41
Cladribine for multiple sclerosis. ( 29449328 )
2018
42
Association between Human Papilloma Virus (HPV) vaccination and risk of Multiple Sclerosis: A systematic review. ( 29333935 )
2018
43
B cell depleting therapy for multiple sclerosis overlapping with neuromyelitis optica spectrum disorder. ( 29621743 )
2018
44
Chronic Cerebro-Spinal Venous Insufficiency in Multiple Sclerosis: Is It the End? ( 29629362 )
2018
45
Natalizumab in secondary progressive multiple sclerosis. ( 29545068 )
2018
46
Improvement During Inpatient Rehabilitation Among Older Adults with Guillain-BarrAc Syndrome, Multiple Sclerosis, Parkinson Disease, and Stroke. ( 29952780 )
2018
47
An epidemiological study on the course of disease and therapeutic considerations in relapsing-remitting multiple sclerosis patients receiving injectable first-line disease-modifying therapies in Germany (EPIDEM). ( 29399053 )
2018
48
Recommendations and Extraction of Clinical Variables of Pediatric Multiple Sclerosis Using Common Data Elements. ( 29652736 )
2018
49
Pediatric multiple sclerosis: a review. ( 29523094 )
2018
50
MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study. ( 29808469 )
2018